It was launched by four universities participating in the Startup Ecosystem Tokyo Consortium (Tokyo Institute of Technology, Keio University, Tokyo Medical and Dental University, and the University of Tokyo), and together with partner institutions in the consortium and other platforms, aims to foster the development of a global university-based startup ecosystem in the Tokyo and other regions. The “Innovation Design Platform (IdP)” aims to foster and nurture a global university startup ecosystem in Tokyo and other regions.
We are holding a meet-up study session to strengthen the network of information sharing among the parties involved in the IdP ecosystem and to create an environment where university-launched ventures can be born. Of course, we welcome those who are not involved in the IdP to participate in order to foster the ecosystem.
For the 5th meeting, we invited Mr. Fumitaka Mori of Taiho Innovations, a corporate venture capital firm of Taiho Pharmaceutical that invests in seed- to early-stage startups in the medical and consumer healthcare fields, to talk about “A venture investor talks about the university-launched startup scene. Mr. Fumitaka Mori of Taiho Innovations will talk about “A Venture Investor’s Perspective on University Startups.
This is a very valuable opportunity for university-launched venture professionals, academic entrepreneurs, VCs, people in the private sector who are planning to collaborate with university-launched ventures, and CVCs to attend this session.
-Date and Time
Tuesday, February 22, 2022, 18:30-20:00
Streamed via Zoom Webinar
18:35-19:05 Part I: “Path to Social Implementation through Entrepreneurship
19:10-19:40 Part II: “Academia Support at Taiho Innovations & TBAP*.
*TBAP: Triple Bridge Acceleration Program
19:40-20:00 Q&A Session
Taiho Innovations LLC ( https://www.taihoinnovations.com/)
Mr. Kurokawa joined Taiho Pharmaceutical in 2003 and has been engaged in drug discovery research.
He then worked in the drug discovery planning department and
He has been involved in the promotion of joint research with universities and venture companies to search for seeds and build drug discovery infrastructure, as well as in the development of new drugs.
He also led the evaluation of early-stage asset introductions and the development of portfolio strategies.
In 2015, he was transferred to Remiges Ventures (an independent VC firm), where he worked on the development of a new drug discovery platform.
Based in Boston, he is in charge of drug discovery venture investments.
He serves as an outside director of the U.S. venture companies in which he invests.
D. (Medical Pharmacy), Graduate School of Pharmaceutical Sciences, University of Shizuoka